ValTech Lifesciences receives the CHF 150,000 Kick to bring the next-generation prosthetic heart valves to patients
23.09.2024
Bringing together state-of-the-art fluid mechanical and cardiovascular engineering research, the Medtech startup ValTech Lifesciences received the final CHF 150,000 kick from Venture Kick to advance its development of a non-thrombogenic, durable heart valve prosthesis.
 ValTech Co-Founders: Shaokai Zheng and Dominik Obrist
|
 |
Valvular heart disease affects over 70 million individuals worldwide, with its prevalence increasing with age. Patients who undergo prosthetic heart valve implantation face significant challenges, including limited valve durability and the lifelong burden of anticoagulation therapy, which is further compounded in regions with limited access to medical resources.
ValTech is advancing cardiovascular health with its patented heart valve features that improve the performance of mechanical and biological prostheses, alleviating the risk of coagulation and extending their lifespan.
The global market for heart valve prostheses was valued at USD 11 billion in 2021 and is estimated to reach USD 25 billion by 2030 with the US, China, and the EU as the largest markets.
ValTech will employ the CHF 150,000 from Venture Kick to accelerate its product development with an industry partner.
As a spin-off project from the University of Bern, the team includes Co-Founders Dr. Shaokai Zheng and Prof. Dr. Dominik Obrist from the Cardiovascular Engineering Lab with more than 30 years of combined experience in fluid mechanics and cardiovascular technology.
“Venture Kick has been a critical source of support to boost our business development,” says Shaokai Zheng, co-founder and CEO of ValTech Lifesciences. “We are now more motivated than ever to bring the next generation heart valve prosthesis to patients.”
ValTech Co-Founders: Shaokai Zheng and Dominik Obrist
ValTech is advancing cardiovascular health with its patented heart valve features that improve the performance of mechanical and biological prostheses, alleviating the risk of coagulation and extending their lifespan.
The global market for heart valve prostheses was valued at USD 11 billion in 2021 and is estimated to reach USD 25 billion by 2030 with the US, China, and the EU as the largest markets.
ValTech will employ the CHF 150,000 from Venture Kick to accelerate its product development with an industry partner.
As a spin-off project from the University of Bern, the team includes Co-Founders Dr. Shaokai Zheng and Prof. Dr. Dominik Obrist from the Cardiovascular Engineering Lab with more than 30 years of combined experience in fluid mechanics and cardiovascular technology.
“Venture Kick has been a critical source of support to boost our business development,” says Shaokai Zheng, co-founder and CEO of ValTech Lifesciences. “We are now more motivated than ever to bring the next generation heart valve prosthesis to patients.”
ValTech Co-Founders: Shaokai Zheng and Dominik Obrist